Anxiety disorders, depression and pain are highly prevalent pathologies. Their pharmacotherapy is associated with unwanted side effects; hence there is a clinical need to develop more effective drugs with fewer adverse reactions.
anxiolytic-like, antidepressant-like and/or antinociceptive properties into account.
Furthermore, their potential in vitro effects towards different targets involved in these pathologies were evaluated. We have obtained twenty chalcones with moderate to high yields and assessed their ability to bind distinctive receptors, from rat brain homogenates, by displacement of labelled specific ligands: 
Introduction
Natural sources are still one of the most important inspirations for the discovery and design of new chemical entities as potential drugs [1] . Chalcones (1,3-diaryl-2-propen-1-ones) ( Fig. 1 ) belong to the flavonoid family. Chemically they consist of two aromatic rings joined by a three-carbon a,b-unsaturated carbonyl system [2] .
Natural and synthetic chalcone derivatives have shown promising biological activity, safety profiles and potential as lead compounds for the discovery of antioxidant, anti-inflammatory, anticancer, anti-infective agents, among others [3] . It was reported that simple and synthetically produced chalcones represent a new challenge For fluorinated derivatives NaOH (25%) was used.
In this work, we have made a survey of bibliographic reports of simple chalcones with anxiolytic, antidepressant and antinociceptive activities to recognize common structural determinants (see Table 1 ). Only few natural and synthetic chalcones have been reported in relation to these pathologies, therefore revealing chalcones as promising scaffold for the development of new derivatives. Most of the reported compounds have a hydroxyl group substitution in position 2 0 .
Also, methoxy, methyl, dimethylamine, halogens and nitro groups substitutions are present in both rings of these derivatives. Additionally, the natural compound isoliquiritigenin (2 0 ,4 0 ,4-trihydroxychalcone) was described as a ligand for the benzodiazepine binding site (BDZ-bs) of the GABA A receptor, with a Ki value of 0.45 mM, being a positive allosteric modulator [12] . Also, we have already reported that the chalcone nucleus itself exhibits moderate affinity for the m-opioid receptor [13] .
Thus, the aim of this work was to synthesize a series of simple chalcones and assess their potential effect on different biological receptors involved in anxiety disorders, depression and pain. Afterwards, those compounds of the series that showed the best affinity for each receptor were tested in different behavioural paradigms related to these pathologies. 
General methods for the synthesis of 2-21
The synthesis of the chalcone derivatives was performed following [26] with some modifications ( Fig. 1 
(2E)-1-(4-aminophenyl)-3-phenyl-2-propen-1-one (14)
Yield 70 %, yellow crystals. 
(2E)-3-(4-chlorophenyl)-1-phenyl-2-propen-1-one (19)
Yield 73%, white crystals. 1 3295). Accordingly, to the ARRIVE guidelines, all possible efforts were made to minimize animal suffering and discomfort and to reduce the number of experimental subjects. The number of animals used was the minimum number, consistent with obtaining significant data. Mice were randomly assigned to any treatment groups and were used only once.
Administrations and procedures
Compounds 1, 9, 12 and DZ were diluted by using the sequential addition of dimethylsulfoxide, a solution of 0.25% Tween 80 and saline; up to final concentrations of 5%, 20% and 75%, respectively. MOR and IMP were dissolved in saline solution.
For each assay, a control group receiving only vehicle (VEH) was tested in parallel with those animals receiving drug treatment. Neither of the tests performed showed significant differences between VEH control mice vs. mice treated with saline (data not shown). The volume of intraperitoneally (i.p.) injections was 0.15e0.30 ml/30 g of body weight. Compounds tested in behavioural assays were evaluated 30 minutes after i.p. administrations. Doses of the chalcones used for in vivo assays in this study were chosen based on pilot experiments and previous reports on similar derivatives (see Table 1 ).
Protein concentration was determined by the Bradford's method using bovine serum albumin as standard [27] . min under red dim light. The total exploratory activity (number of entries in both arms) was also determined [32] . Mice were i.p. injected with 10 mg/kg of compounds 1, 9, 14, 15, 16, and 1 mg/kg of DZ (reference compound) or VEH. Compound 9 was further tested at the doses of 3 mg/kg and 30 mg/kg.
Tail suspension test
The total duration of immobility induced by tail suspension was measured according to the method of Steru and co-workers [33] . It is a useful mouse behavioral test for the screening of potential antidepressant drugs [7] . Mice were individually suspended by their tails to a metal hook (distance from floor: 18 cm) with adhesive tape (distance from tip of tail: 2 cm) for 6 min. Mice, especially at the beginning of the session, manifest several escape oriented behaviours (which constitute mobility) interspersed with temporally increasing bouts of immobility. Further, the dose of 10 mg/kg of compound 12 was also evaluated in this test.
Locomotor activity
The spontaneous locomotor activity was automatically measured as previously described [36] and was expressed as total light beam counts per 5 min. The test was performed 30 min after the i.p. injection of compounds 1, 9 and 12 (10 mg/ kg and 30 mg/kg) or VEH.
Rotarod
The Rotarod test is used to assess a possible motor deficit provoked by test compounds. It measures the ability of the mouse to maintain balance on a rotating rod [37] .
The equipment consists of a cylindrical shaft 3 cm diameter and 50 cm long, horizontally placed on a support and connected to a motor via a pulley. The axis is separated by discs into five compartments where mice are placed.
Mice were i.p. administered with 30 mg/kg of compound 12 or VEH. Each mouse was placed on the rotating rod and the latency time to fall off is measured (cut-off time: 120 s). Previously, mice were subjected to 3 successive trainings, in order to exclude difference in motivation and motor learning, and only those animals that kept the balance for 2 min in all sessions were used in the trial.
Statistical analyses
Binding assays data was analyzed by nonlinear regression fit to one site of specific bound vs radioligand concentration. Ki values were calculated using the Cheng- A P value <0.05 was considered statistically significant. All data were expressed as mean AE S.E.M. and analyzed with GraphPad Prism 5.00 software.
Results and discussion

Chemistry
In Table 2 we present the structures of chalcones that were prepared by ClaisenSchimdt condensation of the corresponding acetophenone and aromatic aldehydes with moderate to high yields (34e88%) (Fig. 1) . The novel chalcone 12 was characterized by 1 H NMR, 13 C NMR, mass spectra and elemental analysis. Table 3 . Those derivatives that showed more than 60% inhibition of radioligands binding to their respective receptors at the concentration of 300 mM, were selected to determine their inhibitory constant (Ki). In all cases, data obtained were best fitted to one site binding hyperbola.
In vitro binding screening
All the synthetic derivatives were able to displace at least one of the radioligands tested. Some of the synthesized compounds showed affinities in the low micromolar range towards the BDZ-bs of the GABA A receptor and moderate to no affinity for mopioid and 5-HT 1A receptors. (Table 3 ).
This is the first report describing the potential involvement of the 5-HT 1A and mopioid receptors on the CNS biological activities of chalcone derivatives.
Pharmacological studies
Those compounds of the series with the highest affinity for each receptor were selected for further in vivo studies. Then, a cut off value of Ki for each receptor was chosen to reduce the number of animals for the in vivo assays.
Elevated plus-maze test
This test is based on the natural aversion of mice to open and elevated areas, as well as on their natural spontaneous exploratory behaviour in novel environments. This assay allows the identification of the anxiolytic-like effects of benzodiazepine-like drugs after their administration in rodents [32] . Chalcones with Ki values less than 6 mM in the BDZ-bs radioligand assay; 1, 9, 14, 15 and 16; were chosen to be tested in this assay. First, mice were tested 30 min after their i.p. injection with 10 mg/kg of the each chalcone (Fig. 2 ).
ANOVA indicated a significant effect on the number of total arm entries [F(5,80) ¼ Alternatively, mice i.p. injected with DZ (1 mg/kg), a classical benzodiazepine ligand used as a reference compound, showed a significant increase in the three parameters (P < 0.001, Fig. 2, inset) .
The results revealed that chalcones 1, 14 and 15 did not exert significant effects at this dose, as neither of the measured parameters were statistically different compared to those of the control group.
The effect of 5 0 -methyl-2 0 -hydroxychalcone (9) in this test was further evaluated at 3, 10 and 30 mg/kg (Fig. 3A) 3 H]-8-OH-DPAT to the 5HT 1A receptor (at 300 mM) indicated as: inhibition >90% (þþþþ); inhibition 60e90% (þþþ); inhibition 40e60% (þþ); inhibition 20e40% (þ) and inhibition <20% (-). b Ki AE standard error of the mean values (SEM) are means of 2 independent determinations. Diazepam, serotonin and naltrexone, reference compounds for the BDZ-bs, 5HT 1A and m-opioid receptors, gave Ki values of 3.5 AE 1.2 nM, 2.2 AE 0.01 nM and 0.2 AE 0.01 nM, respectively. (Fig. 2A) , compared to control group, respectively.
Considering that the parameters measured in the elevated plus-maze test depend on locomotion [41] , the effect of the acute administration chalcone 9 in the spontaneous locomotor activity of mice was evaluated in a separate method (Fig. 3B) . The results evidenced that animals injected with chalcone 9 at 10 and 30 mg/kg did not show significant differences compared with the control group in the locomotor activity test ([F(2,34) ¼ 1.618, P ¼ 0.2140], Fig. 3B) . Therefore, the changes in the parameters measured in the elevated plus-maze test should not be attributed to changes in mice locomotion, but they should be considered an anxiolytic-like effect of compound 9 at 10 mg/kg.
Even though isoliquiritigenin and butein (Table 1) , natural chalcones, showed anxiolytic-like effect in the plus-maze test [42] , 5 0 -methyl-2 0 -hydroxychalcone (9) is the first synthetic chalcone described as anxiolytic with affinity for the BDZ-bs of the GABA A receptor.
Tail suspension test
The tail suspension test is one of the most widely used model for assessing antidepressant-like activity in mice. This test is based on the fact that animals subjected to the short-term, inescapable stress of being suspended by their tail, will develop an immobile posture. Several antidepressant medications reverse the immobility time and promote the occurrence of escape-related behaviour [7] . Also, there is accumulating evidence for a critical involvement of serotonergic receptors, particularly 5-HT 1A , in the pathophysiology and treatment of depression [10, 43, 44, 45] . Several 5-HT 1A agonists decrease the duration of immobility in the in the tail suspension test [46] . Considering the role of the 5-HT 1A receptor in the antidepressant-like activity in rodents and humans [47] , the potential antidepressant-like effect of chalcones with the higher affinities for the 5-HT 1A receptor
tively), were evaluated in mice in the tail suspension test, 30 min after their i.p. injection at the dose of 10 mg/kg (Fig. 4A) . ANOVA analysis evidenced statically differences for the immobility time within experimental groups [F(3,45) ¼ 27.21, P < 0.0001, Fig. 4A ]. The comparison between the VEH control group and experimental groups by the Dunnett's test indicated that chalcone nuclei (1) at 10 mg/kg (P < 0.001) and IMP (a reference compound, a tricyclic antidepressant mainly acting as a norepinephrine uptake blocker) at 30 mg/kg (P < 0.001) significantly reduced the immobility time of mice. In contrast, compound 5 (10 mg/kg) was not active in this test (Fig. 4A) .
The effect of compound 1 at different i.p. doses (3, 10 and 30 mg/kg) is shown in Even though some authors have used the chalcone scaffold to synthesize novel derivatives with a similar antidepressant-like activity, as the one of fluoxetine (selective serotonin reuptake inhibitor (SSRI) class) in the tail suspension and forced swimming tests (Table 1) , the effect of this nucleus per se has not been reported in any of these studies [16, 18] .
The study of the mechanism of action of the reported 3-bromo-2 0 ,4 0 -dihydroxychalcone and 2,6-dichloro -2 0 ,4 0 -dihydroxychalcone (Table 1) showed that they significantly increased head-twitches in mice and enhanced the mouse lethality in the 5-HT induced head-twitch and yohimbine-induced mortality test. These results indicate that the serotonergic, but not the noradrenergic system, is involved in the antidepressant-like effect of these compounds [16] .
On the other hand, some reports also revealed that several flavonoids may exert their antidepressant effect by increasing the bioamine content, thereby restraining the reuptake of bioamines by synaptosomes or by inhibiting monoamine oxidases (MAO)
activities [48] . For the chalcone nucleous itsef it was already reported an IC 50 value of 1.41 AE 0.070 mM for the hMAO B and no effect for the hMAO A enzymes [49] . So, future experiments should be performed to determine if the mechanism of action ***P < 0.001, *P < 0.05, **P < 0.01, significantly different from vehicle (VEH).
of the chalcone nuclei for the antidepressant effect relies just on the binding to 5-HT 1A receptors, or whether other mechanisms are needed to develop this effect.
Writhing and hot plate tests
Pain remains a significant clinical problem and m-opioid receptor agonists, such as hydrocodone and morphine, are still the most widely used treatments for moderate to severe pain. However, the use of opioids to treat pain is limited by unwanted effects, such as constipation, respiratory depression, tolerance, and dependence. These side effects also diminish patient's quality of life, decrease compliance, and are particularly problematic in long-term chronic users. These limitations of chronic opioid therapy have spurred drug discovery efforts to develop new analgesic drugs with an improved therapeutic profile.
The antinociceptive activity of the synthesized chalcones with Ki values under 20 mM towards m-opioid receptors, chalcones 6 and 12, was evaluated against chemical and thermal noxious stimuli. First, the acetic acid-induced writhing was performed, as it is a classical model for the assessment of analgesic or anti-inflammatory properties of new agents. This is one of the most sensitive methods, which is able to detect antinociception of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and other centrally acting drugs [24] . The effect of compounds 6 and 12 at the dose of 10 mg/kg in this assay is shown in Fig. 5A . ANOVA of the results obtained yielded statistically significant differences in the number of abdominal cramps Anti-inflammatory activities of chalcones remain first in the list of published biological active analogs [50] , thus its effects in the writhing test is not unexpected. A number of chalcones and their derivatives have been described as inhibitors of the synthesis of nitric oxide and prostaglandins [2, 3] . Although there is a consistent evidence of chalcones as peripheral analgesic drugs (see Table 1 ), little is known about their centrally antinociceptive action and the involvement of the opioid system. Only few chalcone derivatives were reported as central analgesic acting drugs in chemical and thermal nociception models in mice (see Table 1 and [23, 24, 51] ). Their mechanism of action is not well established as the pretreatment with a non-selective opioid receptor antagonist, naloxone, only reversed the antinociceptive effect of the rigid 3,4-dihydroxychalcone [51] and the natural dimeric chalcones extracted from Myracrodruon urundeuva [23] . In contrast, our study is focused on simple synthetic chalcones as ligands for m-opioid receptors that evidenced central antinociceptive activity.
The antinociceptive effect of compound 12 was further evaluated at 0.3, 3, 10 and 30 mg/kg in the acetic acid-induced writhing (Fig. 5C ) and at 10 and 30 mg/kg in the hot plate test (Fig. 5D ). ANOVA evidenced statistically significant differences in the number of abdominal cramps [F(4,44) ¼ 21.48, P < 0.0001, Fig. 5C ] and in the . Statistical analysis was performed by one-way ANOVA followed by Dunnett's test. *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control group.
reaction time of mice against the thermal stimulus [F(2,27) ¼ 9.628, P ¼ 0.0008, Fig. 5D ]. The results revealed that the doses of 3, 10 and 30 mg/kg significantly reduced the number of writhes with 59.7%, 62.6%, 96.1% inhibition of constrictions compared to VEH control group (P < 0.0001, Dunnett's test).
The comparison of the latency time in the hot plate test between the VEH control group and experimental groups by the Dunnett's test indicated that the dose of 30 mg/kg significantly increased the latency time of mice in this assay (P < 0.001).
Lastly, in order to discard any motor abnormalities that could interfere with the parameters measured in the writhing and hot plate tests, the spontaneous locomotor activity (Fig. 5E ) and the balance on the Rotarod assay were measured for chalcone 12.
None of the mice treated with chalcone 12 showed any failure in their locomotion (Fig. 5E ) or to maintain balance on the Rotarod assay (data not shown), evidencing that this chalcone did not produce neurotoxicity or motor impairment, at the doses tested. Therefore, the experimental results presented in this work correspond to genuine antinociceptive effect, as they were not affected by motor abnormalities.
On the other hand, it is important to stress here that none of the chalcone treated animals tested in this work died during the assays.
According to these results, it can be concluded that the antinociceptive activity of chalcone 12 may occur by central and peripheral mechanisms. Opioids are known to show analgesic activities in both hot plate and writhing tests by acting on central and peripheral nociceptive pathways, respectively [52] . Therefore, chalcones scaffold should be also considered for the development of centrally acting antinociceptive drugs.
Cell viability assay on the SH-SY5Y cell line
The absence of adverse effects on a cell line of chalcones 1, 9 and 12 was assessed using a cell viability assay on SH-SY5Y human neuroblastoma cell line (Fig. 6 ).
After treatment for 48 h, chalcone 1 did not affect the cell viability up to 75 mM, compound 9 did not modify the cell viability up to 20 mM meanwhile derivative 12 decreased the cell viability at 20 mM or higher. The active compounds 1, 9
and 12 exhibited 95.9%, 88.5% and 74.8% cell viability at 20 mM, respectively, suggesting that these compounds did not significantly reduce cell viability.
Bloodebrain barrier permeability assay
As we are interested in developing compounds with activity towards cerebral receptors, it is crucial that they can reach its targets. Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the BBB and exhibit CNS activity. In the broadest sense, moderately lipophilic drugs cross the BBB by passive diffusion. Polar molecules are generally poor CNS agents unless they undergo active transport across the CNS [53] . As summarized in Table 2 , cLog P values for compounds 1e21 were above 2; therefore, it can be estimated that they are capable to cross the BBB and reach its target. Furthermore, BBB permeability of the compounds 1, 9 and 12 was assessed using the parallel artificial membrane permeability assay (PAMPA-BBB) [54] . Five commercial drugs were used as references to validate the experimental system and establish the permeability range (-logP e of 7.2e4.6). Traditional pampa binning was used as follows; maxP e > 2*10 À6 cm/s designated as high permeability, maxP e < 0.5*10 À6 cm/s designated as low permeability and intermediate as uncertain. According to the results summarized in Table   4 , all off the tested compounds should be able to cross BBB and reach CNS.
Conclusions
In conclusion, a series of 20 chalcone derivatives were synthesized by condensation of the corresponding acetophenone and aromatic aldehydes with moderate to high yields. Some of the synthesized compounds showed affinities in the low micromolar range towards the BDZ-bs of the GABA A receptor and moderate to no affinity for m-opioid and 5-HT 1A receptors. The most active compounds for each receptor were selected for further in vivo studies. Consequently, chalcones 1, 9, 14, 15 and 16 with good affinity for the BDZ-bs of the GABA A receptor, chal- 
